Terumo Blood and Cell Technologies is working to improve treatment for pregnant sickle cell sufferers, publishing first-of-its-kind international consensus recommendations for these patients.
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and the Flow Cytometry Facility at the Babraham Institute have announced a collaboration to develop a bespoke cell phenotyping...
Terumo Blood and Cell Technologies have announced US Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System.
Scarlet Therapeutics, a leader in red blood cell-based therapeutics, has raised seed funding from Science Creates Ventures and Meltwind to develop its platform and build a pipeline of novel therapies.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
Novartis will install Berkeley Lights’ Beacon antibody discovery technology, the sixth large pharmaceutical firm to adopt the platform in less than a year.
Shire has begun adding capability within its own network to manufacture the Hereditary Angioedema (HAE) product Cinryze, currently being made by Dutch CMO Sanquin.
Acticor Biotech has made a deal with Merck KGaA’s CMO MilliporeSigma to use its Provantage End-to-End services to make its anti-thrombotic antibody fragment ACT-017 for stroke.
CSL Behring will target growing Russian demand for protein-based therapies through a new Moscow office but says for now there are no plans for a local manufacturing site.
Shire will use contractors to increase production of Cinryze, the half billion dollar-a-year Hereditary Angioedema (HAE) drug it bought with ViroPharma in 2014.
China Biologic Products is set to become the second Chinese producer of a prothrombin complex concentrate (PCC) blood clotting product following an inspection by the CFDA
Stemcell Technologies will use BioLife Solutions’ cryopreservation media to ship its new range of stem cell based products under an expanded agreement.
Oxygen therapeutics company Biopure has announced another $3
million (€2.5 million) public offering to boost its working
capital, despite its major drug for humans, Hemopure, an artificial
blood product, being licensed only in South...
